Mourabit Halima, Author at MediaMedic

Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

By Mourabit Halima 2024.09.05

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).

Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

By Mourabit Halima 2024.09.05

On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.

Dr. He Huang: Focusing on the Rise and Challenges of Cellular Immunotherapy | The 8th CSCO Hematology Academic Conference

By Mourabit Halima 2024.09.05

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.

Dr. Zhixiang Shen: Ten Years of Transformative Ideas in Hematological Oncology – From Treatment to Management

By Mourabit Halima 2024.09.05

In the scorching summer, experts gathered in the cool city of Harbin for the 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. Held from July 26 to 28, 2024, this grand event brought together renowned experts and scholars from home and abroad to present on leukemia, lymphoma, and myeloma, sharing research findings and practical experiences. "Oncology Frontier - Hematology Frontier" had the honor of interviewing Dr. Zhixiang Shen, chairman of this conference and a professor at Ruijin Hospital, Shanghai JiaoTong University School of Medicine. He discussed the highlights of the conference, the current status of indolent lymphoma diagnosis and treatment, the concept of chronic disease management in hematological oncology, and future trends in the field.

Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment

By Mourabit Halima 2024.09.05

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.

Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

By Mourabit Halima 2024.09.05

Portal hypertension is a severe complication of chronic liver disease, directly associated with clinical outcomes such as ascites and variceal bleeding. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment that significantly reduces portal pressure. Portal pressure gradient (PPG) is commonly used to assess portal pressure in patients undergoing TIPS. Recently, a study led by Dr. Guohong Han's team from Xi'an International Medical Center Hospital, published in the Journal of Hepatology, explored the optimal timing and hemodynamic target for measuring PPG in cirrhotic patients with variceal bleeding after undergoing TIPS with covered stents.

Interventional Therapy in Hepatobiliary Diseases | Dr. Xuefeng Luo: In-depth Analysis of the French Guidelines on Transjugular Intrahepatic Portosyste

By Mourabit Halima 2024.09.04

Interventional therapy is an emerging clinical discipline and an important part of minimally invasive medicine. It stands as the third major clinical discipline, distinct from traditional internal medicine and surgery. Interventional therapy allows the treatment of various diseases through tiny channels a few millimeters in diameter created in the skin, using advanced imaging technologies such as DSA, ultrasound, and CT, without the need for large incisions to expose the lesion. Special needles, catheters, drugs, or stents are employed to treat the affected organs and tissues. To provide cutting-edge advancements in interventional hepatology, Hepatology Digest has partnered with Dr. Xuefeng Luo from West China Hospital of Sichuan University to create the "Interventional Therapy in Hepatobiliary Diseases" column. This monthly column aims to share the latest research, convey standardized treatment concepts, and track the latest developments in interventional therapy, with the goal of benefiting experts, researchers, and frontline medical workers in the field.

Dynamic Changes in Circulating Tumor DNA in Hepatocellular Carcinoma Patients Reveal Its Potential as a Non-Invasive Biomarker

By Mourabit Halima 2024.09.04

A recent clinical study conducted by Dr. Jean-Charles Nault and his team at the Cordeliers Research Center of Sorbonne University, France, was published in Gut journal. This study reveals the dynamic changes in circulating tumor DNA (ctDNA) in patients with hepatocellular carcinoma (HCC) and its clinical significance. The findings provide new perspectives and tools for the clinical management of HCC, highlighting the potential of ctDNA monitoring as an important adjunct in the diagnosis and treatment of HCC.

Newly Released! IDSA 2024 Guidelines for Treating Resistant Gram-Negative Bacterial Infections

By Mourabit Halima 2024.09.04

As antimicrobial resistance (AMR) continues to be a growing global public health challenge, treating infections caused by resistant bacteria has become increasingly difficult. Recently, the Infectious Diseases Society of America (IDSA) released the "IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections," providing clinicians with valuable treatment recommendations. This document primarily addresses infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), AmpC beta-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia, offering specific and comprehensive treatment advice. Infectious Disease Frontier has translated and summarized the relevant recommendations from the document for reference by our readers.

Dr. Steven Narod: Bilateral Mastectomy and Breast Cancer Mortality—A Rethink of Clinical Guidelines

By Mourabit Halima 2024.09.04

In recent years, bilateral mastectomy, as a surgical approach to prevent contralateral breast cancer, has gained a certain degree of attention and application. However, there is still controversy regarding the actual effectiveness of bilateral mastectomy in preventing breast cancer mortality. Recently, Dr. Steven Narod from the Dalla Lana School of Public Health published a research paper titled "Bilateral Mastectomy and Breast Cancer Mortality" in JAMA Oncology. "Oncology Frontier" specially invited Dr. Steven Narod to share his latest research findings, hoping to provide more thoughts and guidance for the prevention, diagnosis, and treatment of breast cancer.